Using specific drugs to improve treatment outcomes for glioblastoma patients
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM
This study is looking at how certain drugs can make radiation therapy work better for people with glioblastoma, a type of brain cancer, by finding out which combinations of treatments are most effective for each patient.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11212238 on NIH RePORTER |
What this research studies
This research investigates how certain compounds from the NCI CTEP portfolio can be used to enhance the effectiveness of radiation therapy for glioblastoma, a type of brain cancer. The approach focuses on identifying biomarkers that predict which drug combinations will work best in preventing the cancer from changing its characteristics in response to treatment. By studying glioblastoma stem cells and their progeny, the research aims to develop personalized treatment strategies that optimize radiation therapy outcomes for patients. The study will utilize advanced techniques to track cancer cells and assess the impact of various drug combinations in laboratory settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing or considering radiation therapy.
Not a fit: Patients with other types of brain tumors or those who are not eligible for radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for glioblastoma patients, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using biomarker-driven approaches to enhance cancer treatment, suggesting that this study's methodology could yield valuable insights.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Pajonk, Frank — University of California Los Angeles
- Study coordinator: Pajonk, Frank
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.